ch. de la Dent d’Oche 1A
9 articles with Anokion
Anokion Presents New Data Describing Transformative Therapeutic Approach for Treatment of Multiple Sclerosis at ECTRIMS Congress
Induction of Antigen-Specific Immune Tolerance Using Proprietary Technology Represents Novel, Targeted Treatment Modality for Autoimmune Diseases
Anokion Acquires Kanyos Bio and Raises $40 Million to Advance First Product Candidate into Clinic in 2019
Anokion SA announced the acquisition of Kanyos Bio, Inc. and the completion of a $40 million Series B financing.
First trial of novel immune tolerance therapies expected this year
Anokion Expands Leadership Team with Appointment of Deborah Geraghty, Ph.D., as Chief Business Officer
Stephan Kontos, Ph.D., promoted to Chief Scientific Officer Tony Rossomando, Ph.D., appointed Vice President, Technical Operations
Dr. Clayman has been an independent director of Anokion since February 2016
Anokion today announced the appointment of John Hohneker, M.D., as president and chief executive officer, effective January 22.